<!DOCTYPE html>
<html lang="tr"><head>
<script src="yara-iyilesmesi-ve-tamir_files/libs/clipboard/clipboard.min.js"></script>
<script src="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/tabby.min.js"></script>
<script src="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/popper.min.js"></script>
<script src="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="yara-iyilesmesi-ve-tamir_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.340">

  <meta name="author" content="Serdar Balcı">
  <title>Yara İyileşmesi ve Tamir</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/dist/theme/quarto.css" id="theme">
  <link href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Yara İyileşmesi ve Tamir</h1>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Serdar Balcı 
</div>
</div>
</div>

</section>
<section id="yara-iyileşmesi-ve-tamir" class="title-slide slide level1 center">
<h1>Yara İyileşmesi ve Tamir</h1>

</section>

<section id="dr.-serdar-balci" class="title-slide slide level1 center">
<h1>Dr.&nbsp;Serdar BALCI</h1>

</section>

<section id="tamir-iyileşme" class="title-slide slide level1 center">
<h1>Tamir (İyileşme)</h1>
<p><strong>Hasar sonrası doku mimarisinin ve aktivitesinin restorasyonu</strong></p>
<p><strong>Hasarlı dokunun rejenerasyonu</strong></p>
<p><strong>Bağ dokuda skar oluşumu</strong></p>
</section>

<section id="rejenerasyon" class="title-slide slide level1 center">
<h1>Rejenerasyon</h1>
<ul>
<li><strong>Hasarlı hücrelerin yerine konması</strong></li>
<li><strong>Normal duruma geri dönüş</strong></li>
<li><strong>rejenerasyon</strong>
<ul>
<li><strong>Proliferasyon kapasitesi devam eden rezidü (hasarsız) hücrelerin bölünmesi</strong></li>
<li><strong>Doku kök hücrelerinin çoğalması</strong></li>
</ul></li>
<li><strong>Deri ve mukozal dokular</strong>
<ul>
<li><strong>Hızlı bölünne epitel</strong></li>
</ul></li>
<li><strong>Karaciğer</strong></li>
</ul>
</section>

<section id="skar-oluşumu-nedbeleşme" class="title-slide slide level1 center">
<h1>Skar oluşumu (Nedbeleşme)</h1>
<p><strong>Rejenerasyon kapasitesi olmayan dokularda</strong></p>
<p><strong>Dokudaki destek yapılarda zarar görümüştür</strong></p>
<p><strong>Tamir fibröz doku oluşumu ile sonuçlanır → skar oluşumu</strong></p>
<p><strong>Kayıp parankimal hücrelerin fonksiyonu yerine getirilemez</strong></p>
<p><strong>Yapısal sağlamlık elde edilmeye çalışılır, böylece rezidü hücreler aktivitelerini yerine getirebilir</strong></p>
<ul>
<li><strong>Kollojenin fazla deoplanması</strong></li>
<li><strong>Akciğer, karaciğer, böbrek</strong>
<ul>
<li><strong>Kronik inflamasyonun sekeli</strong></li>
</ul></li>
<li><strong>Myokard</strong>
<ul>
<li><strong>Yaygın iskemik nekroz (infarkt)</strong></li>
</ul></li>
</ul>
</section>

<section id="organizasyon" class="title-slide slide level1 center">
<h1>Organizasyon</h1>
<p><strong>Organize pnömoni</strong></p>
<p><strong>İnflamatuar eksuda ile dolu bir boşlukta gelişen fibrozis</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir0.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir1.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir2.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="hücre-ve-doku-rejenerasyonu" class="title-slide slide level1 center">
<h1>Hücre ve doku rejenerasyonu</h1>
<p><strong>Hücre ve doku rejenerasyonundaki faktörler</strong></p>
<p><strong>Hücre proliferasyonu</strong></p>
<p><strong>Büyüme Faktörleri</strong></p>
<p><strong>Ekstaselüler Matriks</strong></p>
</section>

<section id="hücre-çoğalmasının-kontrolü" class="title-slide slide level1 center">
<h1>Hücre çoğalmasının kontrolü</h1>
<ul>
<li><strong>Doku iyileşmesi sürecinde çoğalan hücreler</strong></li>
<li><strong>Hasarlı dokudan geri kalanlar</strong>
<ul>
<li><strong>Normal yapıyı geri kazanma</strong></li>
</ul></li>
<li><strong>Vasküler endotelyal hücreler</strong></li>
<li><strong>Fibroblastlar</strong>
<ul>
<li><strong>Skar, nedbe</strong></li>
</ul></li>
</ul>
</section>

<section id="dokuların-çoğalma-kapasiteleri" class="title-slide slide level1 center">
<h1>Dokuların çoğalma kapasiteleri</h1>
<ul>
<li><span style="color:#FF0000">Labil dokular</span>
<ul>
<li><strong>Sürekli bölünürler</strong></li>
<li><strong>Kemik iliğindeki hematopoietik hücreler</strong></li>
<li><strong>Yüzey epitel, duktuslar</strong></li>
<li><strong>Gastrointestinal, Genitoüriner traktus</strong></li>
<li><strong>Bu hücreler hasar sonrası hızlıca rejenere olurlar, kök hücre havuzları yeterli olduğu sürece</strong></li>
</ul></li>
<li><span style="color:#FF0000">Stabil dokular</span>
<ul>
<li><strong>Hücre hasarına ve doku kaybına cevap olarak bölünebilirler</strong></li>
<li><strong>Karaciğer, böbrek, pankreas</strong></li>
<li><strong>Endotel hücreleri, fibroblastlar, düz kas hücreleri</strong></li>
<li><strong>Hasar sonrası rejenerasyon kapasitesi sınırlı</strong>
<ul>
<li><strong>Karaciğerin kapasitesi daha yüksek</strong></li>
</ul></li>
</ul></li>
<li><span style="color:#FF0000">Kalıcı dokular</span>
<ul>
<li><strong>Farklılaşmasını tamamlamış, postnatal dönemde proliferasyon yok</strong></li>
<li><strong>Nöronlar</strong>
<ul>
<li><strong>Kısıtlı kök hücre çoğalması ve farklılaşması var</strong></li>
</ul></li>
<li><strong>Kalp kası hücreleri</strong>
<ul>
<li><strong>Myokard nekrozu sonrası çoğalmanın olduğuna dair deliller var</strong></li>
</ul></li>
<li><strong>İskelet kası</strong>
<ul>
<li><strong>Endomisyal kılıftaki satellit hücrelerde proliferasyon oluyor</strong></li>
</ul></li>
</ul></li>
</ul>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir3.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="kök-hücreler" class="title-slide slide level1 center">
<h1>Kök Hücreler</h1>
<ul>
<li><p><strong>Kendini yenileme kapasitesi</strong></p></li>
<li><p><strong>Asimetrik çoğalma</strong></p>
<ul>
<li><strong>Hücrelerden biri diferansiyasyon yolağına girer ve matür hücre olur</strong></li>
<li><strong>Öbürü undiferansiye kök hücre olarak kalır</strong></li>
</ul></li>
<li><p><strong>Özel mikroçevre, kök hücre nişleri</strong></p></li>
<li><p><strong>Rejeneratif Tıp</strong></p></li>
<li><p><span style="color:#FF0000">Embriyonik kök hücreler</span></p>
<ul>
<li><strong>En un-diferansiye kök hücreler</strong></li>
<li><strong>Blastosis, (inner cell mass of the blastocyst)</strong></li>
<li><strong>Yüksek hücre yenilenme kapasitesi var</strong></li>
<li><strong>Hücre kültüründe diferansiye olmadan bir yıl kalabilirler</strong></li>
<li><strong>3 germ yaprağına da diferansiye olabilecek şekilde uyarılabilirler</strong>
<ul>
<li><strong>Nöronlar, kalp kası, karaciğer ve pankreas adacık hücreleri</strong></li>
</ul></li>
</ul></li>
<li><p><span style="color:#FF0000">Erişkin kök hücreleri (doku kök hücreleri)</span></p>
<ul>
<li><strong>Daha az un-diferansiye</strong></li>
<li><strong>Yenilenme kapasitesi daha kısıtlı</strong></li>
<li><strong>Farklılaşma potansiyeli doku ve organa özgü</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir4.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir5.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir6.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir7.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir8.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir9.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
</section>

<section id="büyüme-faktörleri" class="title-slide slide level1 center">
<h1>Büyüme Faktörleri</h1>
<ul>
<li><strong>Proteinler</strong></li>
<li><strong>Belirli hücrelerin sağkalım ve proliferasyonlarını uyarır</strong></li>
<li><strong>Migrasyon ve farklılaşmayı uyarır</strong></li>
<li><strong>Özgün reseptörlere bağlanır</strong></li>
<li><strong>Gen ekspresyonunu etkiler</strong></li>
<li><strong>Hücrelerin siklusa girmesini ağlar</strong></li>
<li><strong>Hücre siklusunun devam etmesini engelleyn blokları kaldırır</strong></li>
<li><strong>Apoptozu engeller</strong></li>
<li><strong>Mitoz için gerekli proteinlerin yapımını indükler</strong></li>
<li><strong>Büyümeyi kontrol eden genleri uyarır</strong>
<ul>
<li><strong>proto-onkogenler</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir10.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir11.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir12.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir13.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir14.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir15.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="ekstraselüler-matriks" class="title-slide slide level1 center">
<h1>Ekstraselüler matriks</h1>
<ul>
<li><strong>Interstisyel matriks</strong></li>
<li><strong>Bazal membran</strong></li>
<li><strong>Fibröz yapısal proteinler</strong>
<ul>
<li><strong>Kollojenler ve elastin</strong></li>
<li><strong>Gerilmeye karşı direnç ve gerilme sonrası geri dönüş</strong></li>
</ul></li>
<li><strong>Suyla hidrate jeller</strong>
<ul>
<li><strong>Proteoglikan ve hyaluronan</strong></li>
<li><strong>Esneme ve kayganlık</strong></li>
</ul></li>
<li><strong>Adeziv glikoproteinler</strong>
<ul>
<li><strong>Matriks elemanlarını birbirine ve diğer hücrelere bağlarlar</strong></li>
<li><strong>Hücre adhezyon molekülleri</strong></li>
</ul></li>
</ul>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir16.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="ekstraselüler-matriksin-fonksiyonları" class="title-slide slide level1 center">
<h1>Ekstraselüler matriksin fonksiyonları</h1>
<ul>
<li><strong>Mekanik destek</strong>
<ul>
<li><strong>Hücre tutunması ve hücre göçü</strong></li>
<li><strong>Hücre poalritesi</strong></li>
</ul></li>
<li><strong>Hücre proliferasyonunun kontrolü</strong>
<ul>
<li><strong>Büyüme faktörlerinin bağlanması ve salınması</strong></li>
<li><strong>Integrin ailesi ile hücre reseptörlerine sinyal iletimi</strong></li>
</ul></li>
<li><strong>Doku yenilenmesinde iskele çatı görevi</strong></li>
<li><strong>Doku mikroçevrelerinin oluşturulması</strong></li>
<li><strong>Doku yenilenmesi için intakt ESM gereklidir</strong></li>
<li><strong>Eğer ESM hasarlı ise → skar oluşumu</strong></li>
</ul>
</section>

<section id="skar-oluşumu" class="title-slide slide level1 center">
<h1>Skar oluşumu</h1>
<p><strong>Ciddi, kronik hasar</strong></p>
<p><strong>Bölünemeyen hücreler hasara uğradığında</strong></p>
<p><strong>Tamir bağ doku ile olur</strong></p>
<p><strong>Rejenerasyon gösteren hücreler ve skar birlikte olabilir</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir17.png"></p>
<ul>
<li><strong>İnflamatuar yanıt</strong></li>
<li><strong>Anjiogenez</strong></li>
<li><strong>Granülasyon dokusu</strong>
<ul>
<li><strong>Fibroblastların göçü ve proliferasyonu</strong></li>
<li><strong>Bağ doku oluşumu</strong></li>
</ul></li>
<li><strong>Yeniden biçimlenme</strong>
<ul>
<li><strong>Fibröz dokunun matürleşmesi ve yeniden organizasyonu</strong></li>
</ul></li>
<li><strong>Stabil fibröz skar</strong></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir18.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir19.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="tamir-başlangıcı-hasardan-sonra-ilk-24-saat-içinde-başlar" class="title-slide slide level1 center">
<h1>Tamir başlangıcı hasardan sonra ilk 24 saat içinde başlar</h1>
<p><strong>Fibroblastların göçü</strong></p>
<p><strong>Fibroblast ve endotel hücre proliferasyonu</strong></p>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir20.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="granülasyon-dokusu" class="title-slide slide level1 center">
<h1>Granülasyon dokusu</h1>
<p><strong>Çok miktarda damar</strong></p>
<p><strong>Arada lökositler</strong></p>
<p><strong>Makroskopik olarak pembe granüler görünüm</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir21.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir22.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir23.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir24.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="anjiogenez" class="title-slide slide level1 center">
<h1>Anjiogenez</h1>
<ul>
<li><strong>Yeni damar oluşum süreci</strong></li>
<li><strong>Var olan dmarlardan gelişim</strong>
<ul>
<li><strong>Öncelikle venüllerden başlar</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir25.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>İlaç tedavisi açısından aktif bir araştırma alanı</strong></li>
<li><strong>Anjiogenezi arttırmaya yönelik</strong>
<ul>
<li><strong>Aterosklerozlu bir hastada kalp kan akımını arttırmak</strong></li>
</ul></li>
<li><strong>Engellemeye yönelik</strong>
<ul>
<li><strong>Tümör büyümesini engellemek</strong></li>
<li><strong>Patolojik damar büyümesini engellemek</strong>
<ul>
<li><strong>Diabetik retinopati</strong></li>
</ul></li>
</ul></li>
<li><strong>Vazodilatasyon</strong>
<ul>
<li><strong>NO, VEGF</strong></li>
</ul></li>
<li><strong>Perisitlerde ayrılma</strong></li>
<li><strong>Endotelyal hücrelerin göçü</strong></li>
<li><strong>Endotelyal hücrelerin proliferasyonu</strong></li>
<li><strong>Kapiller tübül yapısının oluşumu</strong></li>
<li><strong>Periendotelyal hücrelerin ilerlemesi</strong>
<ul>
<li><strong>Küçük kapillerler için perisitler ve büyük damarlar için düz kas</strong></li>
</ul></li>
<li><strong>Endotelyal proliferasyon ve göçün baskılanması ve bazal membranın oluşması</strong></li>
</ul>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir26.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="fibroblastların-aktivasyonu-ve-bağ-doku-birikimi" class="title-slide slide level1 center">
<h1>Fibroblastların aktivasyonu ve Bağ doku birikimi</h1>
<p><strong>Fibroblastlar hasar bölgesine göç eder ve çoğalır</strong></p>
<p><strong>Bu hücrelerce üretilen ESM proteinleri birikir</strong></p>
<p><strong>Transforming growth factor-β (TGF-β)</strong></p>
<p><strong>Platelet-derived growth factor (PDGF)</strong></p>
<p><strong>Sitokinler</strong></p>
</section>

<section id="bağ-dokunun-yeniden-biçimlendirilmesi" class="title-slide slide level1 center">
<h1>Bağ dokunun yeniden biçimlendirilmesi</h1>
<ul>
<li><strong>ESM yapım ve yıkımı aynı anda olur</strong></li>
<li><strong>Kollojen ve diğer ESM yapıları matriks metalloproteinazlarınca (MMPs) yıkılır</strong>
<ul>
<li><strong>Aktivitesi çinko (Zn) iyonuna bağlı</strong></li>
</ul></li>
<li><strong>Bu aktivite metalloproteinaz inhibitörlerince engellenir (tissue inhibitors of metalloproteinases, TIMPs)</strong></li>
</ul>
</section>

<section id="doku-tamirini-etkileyen-faktörler" class="title-slide slide level1 center">
<h1>Doku tamirini etkileyen faktörler</h1>
<ul>
<li><strong>İnfeksiyon</strong></li>
<li><strong>Beslenme</strong>
<ul>
<li><strong>Vit C</strong></li>
</ul></li>
<li><strong>Glukokortikoidler</strong></li>
<li><strong>Mekanik etkiler</strong></li>
<li><strong>Kötü perfüzyon</strong>
<ul>
<li><strong>Arterioskleroz, diabet, venöz tıkanıklık</strong></li>
</ul></li>
<li><strong>Yabancı cisimler</strong></li>
<li><strong>Hasara uğrayan dokunun tipi</strong></li>
<li><strong>Hasarın yeri (parankimal organ, kavite)</strong></li>
<li><strong>Hücre büyümesinde ve ESM yapımındaki sorunlar</strong>
<ul>
<li><strong>Keloid oluşumu (fazla fibroblastik büyüme)</strong></li>
<li><strong>Fazla granülasyon dokusu oluşumu (epitelizasyonu engeller)</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir27.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir28.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="cilt-yaralanmalarının-iyileşmesi" class="title-slide slide level1 center">
<h1>Cilt yaralanmalarının iyileşmesi</h1>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir29.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="primer-iyileşme" class="title-slide slide level1 center">
<h1>Primer iyileşme</h1>
<p><strong>Temiz, enfekte olmayan cerrahi kesi</strong></p>
<p><strong>Cerrahi sütürlerle yaklaştırılmış</strong></p>
<p><strong>Epitelyal bazal membran devamlılığında fokal bozulma</strong></p>
<p><strong>Görece az epitelyal ve konnektif doku ölümü</strong></p>
<p><strong>Tamirin temelinde epitelyal rejenerasyon var</strong></p>
<p><strong>Küçük bir skar oluşur</strong></p>
<p><strong>Minimal yara kontraksiyonu olur</strong></p>
<p><strong>İnsizyon bölgesi öncelikle fibrin pıhtısı ile dolar</strong></p>
<p><strong>Granülasyon dokusu hızlıca gelişir</strong></p>
<p><strong>Yeni epitelle kapatılır</strong></p>
<p><strong>İlk 24 saat</strong></p>
<p><strong>İnsizyon sahasındaki fibrin içine nötrofiller ilerler</strong></p>
<p><strong>Epidermiste kesilen yerlere komşu bazal hücrelerde mitotik aktivite artar</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir30.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>24-48 saat</strong></p>
<p><strong>Her iki uçtaki epite</strong></p>
<p><strong>Epithelial cells from both edges have begun to migrate and proliferate along the dermis</strong></p>
<p><strong>Deposite basement membrane components as they progress</strong></p>
<p><strong>The cells meet in the midline beneath the surface scab</strong></p>
<p><strong>A thin but continuous epithelial layer.</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir31.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-first-intention" class="title-slide slide level1 center">
<h1>Healing by First Intention</h1>
<p><strong>By day 3</strong></p>
<p><strong>Neutrophils replaced by macrophages</strong></p>
<p><strong>Granulation tissue progressively invades the incision space</strong></p>
<p><strong>Collagen fibers are evident at the incision margins, but these are vertically oriented and do not bridge the incision</strong></p>
<p><strong>Epithelial cell proliferation continues, yielding a thickened epidermal covering layer</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir32.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>By day 5</strong></p>
<p><strong>Neovascularization reaches its peak</strong></p>
<p><strong>Granulation tissue fills the incisional space</strong></p>
<p><strong>Collagen fibrils become more abundant and begin to bridge the incision</strong></p>
<p><strong>The epidermis recovers its normal thickness</strong></p>
<p><strong>Differentiation of surface cells yields a mature epidermal architecture with surface keratinization</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir33.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Second week</strong></p>
<p><strong>Continued collagen accumulation and fibroblast proliferation</strong></p>
<p><strong>The leukocyte infiltrate, edema, and increased vascularity are substantially diminished</strong></p>
<p><strong>Increasing collagen deposition within the incisional scar</strong></p>
<p><strong>Regression of vascular channels</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir34.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>By the end of the first month</strong></p>
<p><strong>Scar consists of a cellular connective tissue</strong></p>
<p><strong>No inflammatory cells</strong></p>
<p><strong>Covered by a normal epidermis</strong></p>
<p><strong>Dermal appendages destroyed in the line of the incision are permanently lost The tensile strength of the wound increases with time</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir35.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention" class="title-slide slide level1 center">
<h1>Healing by Second Intention</h1>
<ul>
<li><strong>When cell or tissue loss is more extensive</strong></li>
<li><strong>Large wounds</strong></li>
<li><strong>Sites of abscess formation</strong></li>
<li><strong>Ulceration</strong></li>
<li><strong>Ischemic necrosis (infarction) in parenchymal organs</strong></li>
<li><strong>The repair process is more complex </strong>
<ul>
<li><strong>involves a combination of regeneration and scarring</strong></li>
</ul></li>
</ul>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir36.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention-secondary-union" class="title-slide slide level1 center">
<h1>Healing by Second Intention (secondary union)</h1>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir37.png" class="r-stretch"><p><strong>Inflammatory reaction is more intense</strong></p>
<p><strong>Abundant granulation tissue</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention-1" class="title-slide slide level1 center">
<h1>Healing by Second Intention</h1>
<p><strong>Accumulation of ECM and formation of a large scar</strong></p>
<p><strong>Followed by wound contraction by myofibroblasts</strong></p>

<img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir38.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-of-skin-wounds" class="title-slide slide level1 center">
<h1>Healing of Skin Wounds</h1>
<p><strong>Wound strength</strong></p>
<p><strong>70% to 80% of normal by 3 months</strong></p>
<p><strong>Usually does not improve</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir39.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir40.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir41.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir42.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-%C4%B0yile%C5%9Fmesi-ve-Tamir43.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="fibrosis-in-parenchymal-organs" class="title-slide slide level1 center">
<h1>Fibrosis in Parenchymal Organs</h1>
<p><strong>Excessive deposition of collagen and other ECM components in a tissue</strong></p>
<p><strong>Deposition of collagen in chronic diseases.</strong></p>
<p><strong>The basic mechanisms of fibrosis are the same as those of scar formation during tissue repair</strong></p>
<p><strong>Tissue repair occurs after a short-lived injurious stimulus, follows an orderly sequence of steps</strong></p>
<p><strong>Fibrosis is induced by persistent injurious stimuli </strong></p>
<p><strong>Responsible for organ dysfunction and even organ failure</strong></p>
</section>

<section id="yara-iyileşmesi-ve-tamir-1" class="title-slide slide level1 center">
<h1>Yara İyileşmesi ve Tamir</h1>

</section>

<section id="dr.-serdar-balci-1" class="title-slide slide level1 center">
<h1>Dr.&nbsp;Serdar BALCI</h1>

</section>

<section id="tamir-iyileşme-1" class="title-slide slide level1 center">
<h1>Tamir (İyileşme)</h1>
<p><strong>Hasar sonrası doku mimarisinin ve aktivitesinin restorasyonu</strong></p>
<p><strong>Hasarlı dokunun rejenerasyonu</strong></p>
<p><strong>Bağ dokuda skar oluşumu</strong></p>
</section>

<section id="rejenerasyon-1" class="title-slide slide level1 center">
<h1>Rejenerasyon</h1>
<ul>
<li><strong>Hasarlı hücrelerin yerine konması</strong></li>
<li><strong>Normal duruma geri dönüş</strong></li>
<li><strong>rejenerasyon</strong>
<ul>
<li><strong>Proliferasyon kapasitesi devam eden rezidü (hasarsız) hücrelerin bölünmesi</strong></li>
<li><strong>Doku kök hücrelerinin çoğalması</strong></li>
</ul></li>
<li><strong>Deri ve mukozal dokular</strong>
<ul>
<li><strong>Hızlı bölünne epitel</strong></li>
</ul></li>
<li><strong>Karaciğer</strong></li>
</ul>
</section>

<section id="skar-oluşumu-nedbeleşme-1" class="title-slide slide level1 center">
<h1>Skar oluşumu (Nedbeleşme)</h1>
<p><strong>Rejenerasyon kapasitesi olmayan dokularda</strong></p>
<p><strong>Dokudaki destek yapılarda zarar görümüştür</strong></p>
<p><strong>Tamir fibröz doku oluşumu ile sonuçlanır → skar oluşumu</strong></p>
<p><strong>Kayıp parankimal hücrelerin fonksiyonu yerine getirilemez</strong></p>
<p><strong>Yapısal sağlamlık elde edilmeye çalışılır, böylece rezidü hücreler aktivitelerini yerine getirebilir</strong></p>
<ul>
<li><strong>Kollojenin fazla deoplanması</strong></li>
<li><strong>Akciğer, karaciğer, böbrek</strong>
<ul>
<li><strong>Kronik inflamasyonun sekeli</strong></li>
</ul></li>
<li><strong>Myokard</strong>
<ul>
<li><strong>Yaygın iskemik nekroz (infarkt)</strong></li>
</ul></li>
</ul>
</section>

<section id="organizasyon-1" class="title-slide slide level1 center">
<h1>Organizasyon</h1>
<p><strong>Organize pnömoni</strong></p>
<p><strong>İnflamatuar eksuda ile dolu bir boşlukta gelişen fibrozis</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B10.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B11.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B12.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="hücre-ve-doku-rejenerasyonu-1" class="title-slide slide level1 center">
<h1>Hücre ve doku rejenerasyonu</h1>
<p><strong>Hücre ve doku rejenerasyonundaki faktörler</strong></p>
<p><strong>Hücre proliferasyonu</strong></p>
<p><strong>Büyüme Faktörleri</strong></p>
<p><strong>Ekstaselüler Matriks</strong></p>
</section>

<section id="hücre-çoğalmasının-kontrolü-1" class="title-slide slide level1 center">
<h1>Hücre çoğalmasının kontrolü</h1>
<ul>
<li><strong>Doku iyileşmesi sürecinde çoğalan hücreler</strong></li>
<li><strong>Hasarlı dokudan geri kalanlar</strong>
<ul>
<li><strong>Normal yapıyı geri kazanma</strong></li>
</ul></li>
<li><strong>Vasküler endotelyal hücreler</strong></li>
<li><strong>Fibroblastlar</strong>
<ul>
<li><strong>Skar, nedbe</strong></li>
</ul></li>
</ul>
</section>

<section id="dokuların-çoğalma-kapasiteleri-1" class="title-slide slide level1 center">
<h1>Dokuların çoğalma kapasiteleri</h1>
<ul>
<li><span style="color:#FF0000">Labil dokular</span>
<ul>
<li><strong>Sürekli bölünürler</strong></li>
<li><strong>Kemik iliğindeki hematopoietik hücreler</strong></li>
<li><strong>Yüzey epitel, duktuslar</strong></li>
<li><strong>Gastrointestinal, Genitoüriner traktus</strong></li>
<li><strong>Bu hücreler hasar sonrası hızlıca rejenere olurlar, kök hücre havuzları yeterli olduğu sürece</strong></li>
</ul></li>
<li><span style="color:#FF0000">Stabil dokular</span>
<ul>
<li><strong>Hücre hasarına ve doku kaybına cevap olarak bölünebilirler</strong></li>
<li><strong>Karaciğer, böbrek, pankreas</strong></li>
<li><strong>Endotel hücreleri, fibroblastlar, düz kas hücreleri</strong></li>
<li><strong>Hasar sonrası rejenerasyon kapasitesi sınırlı</strong>
<ul>
<li><strong>Karaciğerin kapasitesi daha yüksek</strong></li>
</ul></li>
</ul></li>
<li><span style="color:#FF0000">Kalıcı dokular</span>
<ul>
<li><strong>Farklılaşmasını tamamlamış, postnatal dönemde proliferasyon yok</strong></li>
<li><strong>Nöronlar</strong>
<ul>
<li><strong>Kısıtlı kök hücre çoğalması ve farklılaşması var</strong></li>
</ul></li>
<li><strong>Kalp kası hücreleri</strong>
<ul>
<li><strong>Myokard nekrozu sonrası çoğalmanın olduğuna dair deliller var</strong></li>
</ul></li>
<li><strong>İskelet kası</strong>
<ul>
<li><strong>Endomisyal kılıftaki satellit hücrelerde proliferasyon oluyor</strong></li>
</ul></li>
</ul></li>
</ul>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B13.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="kök-hücreler-1" class="title-slide slide level1 center">
<h1>Kök Hücreler</h1>
<ul>
<li><p><strong>Kendini yenileme kapasitesi</strong></p></li>
<li><p><strong>Asimetrik çoğalma</strong></p>
<ul>
<li><strong>Hücrelerden biri diferansiyasyon yolağına girer ve matür hücre olur</strong></li>
<li><strong>Öbürü undiferansiye kök hücre olarak kalır</strong></li>
</ul></li>
<li><p><strong>Özel mikroçevre, kök hücre nişleri</strong></p></li>
<li><p><strong>Rejeneratif Tıp</strong></p></li>
<li><p><span style="color:#FF0000">Embriyonik kök hücreler</span></p>
<ul>
<li><strong>En un-diferansiye kök hücreler</strong></li>
<li><strong>Blastosis, (inner cell mass of the blastocyst)</strong></li>
<li><strong>Yüksek hücre yenilenme kapasitesi var</strong></li>
<li><strong>Hücre kültüründe diferansiye olmadan bir yıl kalabilirler</strong></li>
<li><strong>3 germ yaprağına da diferansiye olabilecek şekilde uyarılabilirler</strong>
<ul>
<li><strong>Nöronlar, kalp kası, karaciğer ve pankreas adacık hücreleri</strong></li>
</ul></li>
</ul></li>
<li><p><span style="color:#FF0000">Erişkin kök hücreleri (doku kök hücreleri)</span></p>
<ul>
<li><strong>Daha az un-diferansiye</strong></li>
<li><strong>Yenilenme kapasitesi daha kısıtlı</strong></li>
<li><strong>Farklılaşma potansiyeli doku ve organa özgü</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B14.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B15.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B16.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B17.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B18.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B19.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
</section>

<section id="büyüme-faktörleri-1" class="title-slide slide level1 center">
<h1>Büyüme Faktörleri</h1>
<ul>
<li><strong>Proteinler</strong></li>
<li><strong>Belirli hücrelerin sağkalım ve proliferasyonlarını uyarır</strong></li>
<li><strong>Migrasyon ve farklılaşmayı uyarır</strong></li>
<li><strong>Özgün reseptörlere bağlanır</strong></li>
<li><strong>Gen ekspresyonunu etkiler</strong></li>
<li><strong>Hücrelerin siklusa girmesini ağlar</strong></li>
<li><strong>Hücre siklusunun devam etmesini engelleyn blokları kaldırır</strong></li>
<li><strong>Apoptozu engeller</strong></li>
<li><strong>Mitoz için gerekli proteinlerin yapımını indükler</strong></li>
<li><strong>Büyümeyi kontrol eden genleri uyarır</strong>
<ul>
<li><strong>proto-onkogenler</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B110.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B111.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B112.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B113.png"></p>
<p><strong>Robbins and Cotran’s Pathological Basis of Diseases</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B114.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B115.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="ekstraselüler-matriks-1" class="title-slide slide level1 center">
<h1>Ekstraselüler matriks</h1>
<ul>
<li><strong>Interstisyel matriks</strong></li>
<li><strong>Bazal membran</strong></li>
<li><strong>Fibröz yapısal proteinler</strong>
<ul>
<li><strong>Kollojenler ve elastin</strong></li>
<li><strong>Gerilmeye karşı direnç ve gerilme sonrası geri dönüş</strong></li>
</ul></li>
<li><strong>Suyla hidrate jeller</strong>
<ul>
<li><strong>Proteoglikan ve hyaluronan</strong></li>
<li><strong>Esneme ve kayganlık</strong></li>
</ul></li>
<li><strong>Adeziv glikoproteinler</strong>
<ul>
<li><strong>Matriks elemanlarını birbirine ve diğer hücrelere bağlarlar</strong></li>
<li><strong>Hücre adhezyon molekülleri</strong></li>
</ul></li>
</ul>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B116.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="ekstraselüler-matriksin-fonksiyonları-1" class="title-slide slide level1 center">
<h1>Ekstraselüler matriksin fonksiyonları</h1>
<ul>
<li><strong>Mekanik destek</strong>
<ul>
<li><strong>Hücre tutunması ve hücre göçü</strong></li>
<li><strong>Hücre poalritesi</strong></li>
</ul></li>
<li><strong>Hücre proliferasyonunun kontrolü</strong>
<ul>
<li><strong>Büyüme faktörlerinin bağlanması ve salınması</strong></li>
<li><strong>Integrin ailesi ile hücre reseptörlerine sinyal iletimi</strong></li>
</ul></li>
<li><strong>Doku yenilenmesinde iskele çatı görevi</strong></li>
<li><strong>Doku mikroçevrelerinin oluşturulması</strong></li>
<li><strong>Doku yenilenmesi için intakt ESM gereklidir</strong></li>
<li><strong>Eğer ESM hasarlı ise → skar oluşumu</strong></li>
</ul>
</section>

<section id="skar-oluşumu-1" class="title-slide slide level1 center">
<h1>Skar oluşumu</h1>
<p><strong>Ciddi, kronik hasar</strong></p>
<p><strong>Bölünemeyen hücreler hasara uğradığında</strong></p>
<p><strong>Tamir bağ doku ile olur</strong></p>
<p><strong>Rejenerasyon gösteren hücreler ve skar birlikte olabilir</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B117.png"></p>
<ul>
<li><strong>İnflamatuar yanıt</strong></li>
<li><strong>Anjiogenez</strong></li>
<li><strong>Granülasyon dokusu</strong>
<ul>
<li><strong>Fibroblastların göçü ve proliferasyonu</strong></li>
<li><strong>Bağ doku oluşumu</strong></li>
</ul></li>
<li><strong>Yeniden biçimlenme</strong>
<ul>
<li><strong>Fibröz dokunun matürleşmesi ve yeniden organizasyonu</strong></li>
</ul></li>
<li><strong>Stabil fibröz skar</strong></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B118.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B119.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="tamir-başlangıcı-hasardan-sonra-ilk-24-saat-içinde-başlar-1" class="title-slide slide level1 center">
<h1>Tamir başlangıcı hasardan sonra ilk 24 saat içinde başlar</h1>
<p><strong>Fibroblastların göçü</strong></p>
<p><strong>Fibroblast ve endotel hücre proliferasyonu</strong></p>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B120.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="granülasyon-dokusu-1" class="title-slide slide level1 center">
<h1>Granülasyon dokusu</h1>
<p><strong>Çok miktarda damar</strong></p>
<p><strong>Arada lökositler</strong></p>
<p><strong>Makroskopik olarak pembe granüler görünüm</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B121.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B122.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B123.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B124.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="anjiogenez-1" class="title-slide slide level1 center">
<h1>Anjiogenez</h1>
<ul>
<li><strong>Yeni damar oluşum süreci</strong></li>
<li><strong>Var olan dmarlardan gelişim</strong>
<ul>
<li><strong>Öncelikle venüllerden başlar</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B125.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>İlaç tedavisi açısından aktif bir araştırma alanı</strong></li>
<li><strong>Anjiogenezi arttırmaya yönelik</strong>
<ul>
<li><strong>Aterosklerozlu bir hastada kalp kan akımını arttırmak</strong></li>
</ul></li>
<li><strong>Engellemeye yönelik</strong>
<ul>
<li><strong>Tümör büyümesini engellemek</strong></li>
<li><strong>Patolojik damar büyümesini engellemek</strong>
<ul>
<li><strong>Diabetik retinopati</strong></li>
</ul></li>
</ul></li>
<li><strong>Vazodilatasyon</strong>
<ul>
<li><strong>NO, VEGF</strong></li>
</ul></li>
<li><strong>Perisitlerde ayrılma</strong></li>
<li><strong>Endotelyal hücrelerin göçü</strong></li>
<li><strong>Endotelyal hücrelerin proliferasyonu</strong></li>
<li><strong>Kapiller tübül yapısının oluşumu</strong></li>
<li><strong>Periendotelyal hücrelerin ilerlemesi</strong>
<ul>
<li><strong>Küçük kapillerler için perisitler ve büyük damarlar için düz kas</strong></li>
</ul></li>
<li><strong>Endotelyal proliferasyon ve göçün baskılanması ve bazal membranın oluşması</strong></li>
</ul>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B126.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="fibroblastların-aktivasyonu-ve-bağ-doku-birikimi-1" class="title-slide slide level1 center">
<h1>Fibroblastların aktivasyonu ve Bağ doku birikimi</h1>
<p><strong>Fibroblastlar hasar bölgesine göç eder ve çoğalır</strong></p>
<p><strong>Bu hücrelerce üretilen ESM proteinleri birikir</strong></p>
<p><strong>Transforming growth factor-β (TGF-β)</strong></p>
<p><strong>Platelet-derived growth factor (PDGF)</strong></p>
<p><strong>Sitokinler</strong></p>
</section>

<section id="bağ-dokunun-yeniden-biçimlendirilmesi-1" class="title-slide slide level1 center">
<h1>Bağ dokunun yeniden biçimlendirilmesi</h1>
<ul>
<li><strong>ESM yapım ve yıkımı aynı anda olur</strong></li>
<li><strong>Kollojen ve diğer ESM yapıları matriks metalloproteinazlarınca (MMPs) yıkılır</strong>
<ul>
<li><strong>Aktivitesi çinko (Zn) iyonuna bağlı</strong></li>
</ul></li>
<li><strong>Bu aktivite metalloproteinaz inhibitörlerince engellenir (tissue inhibitors of metalloproteinases, TIMPs)</strong></li>
</ul>
</section>

<section id="doku-tamirini-etkileyen-faktörler-1" class="title-slide slide level1 center">
<h1>Doku tamirini etkileyen faktörler</h1>
<ul>
<li><strong>İnfeksiyon</strong></li>
<li><strong>Beslenme</strong>
<ul>
<li><strong>Vit C</strong></li>
</ul></li>
<li><strong>Glukokortikoidler</strong></li>
<li><strong>Mekanik etkiler</strong></li>
<li><strong>Kötü perfüzyon</strong>
<ul>
<li><strong>Arterioskleroz, diabet, venöz tıkanıklık</strong></li>
</ul></li>
<li><strong>Yabancı cisimler</strong></li>
<li><strong>Hasara uğrayan dokunun tipi</strong></li>
<li><strong>Hasarın yeri (parankimal organ, kavite)</strong></li>
<li><strong>Hücre büyümesinde ve ESM yapımındaki sorunlar</strong>
<ul>
<li><strong>Keloid oluşumu (fazla fibroblastik büyüme)</strong></li>
<li><strong>Fazla granülasyon dokusu oluşumu (epitelizasyonu engeller)</strong></li>
</ul></li>
</ul>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B127.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B128.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="cilt-yaralanmalarının-iyileşmesi-1" class="title-slide slide level1 center">
<h1>Cilt yaralanmalarının iyileşmesi</h1>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B129.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="primer-iyileşme-1" class="title-slide slide level1 center">
<h1>Primer iyileşme</h1>
<p><strong>Temiz, enfekte olmayan cerrahi kesi</strong></p>
<p><strong>Cerrahi sütürlerle yaklaştırılmış</strong></p>
<p><strong>Epitelyal bazal membran devamlılığında fokal bozulma</strong></p>
<p><strong>Görece az epitelyal ve konnektif doku ölümü</strong></p>
<p><strong>Tamirin temelinde epitelyal rejenerasyon var</strong></p>
<p><strong>Küçük bir skar oluşur</strong></p>
<p><strong>Minimal yara kontraksiyonu olur</strong></p>
<p><strong>İnsizyon bölgesi öncelikle fibrin pıhtısı ile dolar</strong></p>
<p><strong>Granülasyon dokusu hızlıca gelişir</strong></p>
<p><strong>Yeni epitelle kapatılır</strong></p>
<p><strong>İlk 24 saat</strong></p>
<p><strong>İnsizyon sahasındaki fibrin içine nötrofiller ilerler</strong></p>
<p><strong>Epidermiste kesilen yerlere komşu bazal hücrelerde mitotik aktivite artar</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B130.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>24-48 saat</strong></p>
<p><strong>Her iki uçtaki epite</strong></p>
<p><strong>Epithelial cells from both edges have begun to migrate and proliferate along the dermis</strong></p>
<p><strong>Deposite basement membrane components as they progress</strong></p>
<p><strong>The cells meet in the midline beneath the surface scab</strong></p>
<p><strong>A thin but continuous epithelial layer.</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B131.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-first-intention-1" class="title-slide slide level1 center">
<h1>Healing by First Intention</h1>
<p><strong>By day 3</strong></p>
<p><strong>Neutrophils replaced by macrophages</strong></p>
<p><strong>Granulation tissue progressively invades the incision space</strong></p>
<p><strong>Collagen fibers are evident at the incision margins, but these are vertically oriented and do not bridge the incision</strong></p>
<p><strong>Epithelial cell proliferation continues, yielding a thickened epidermal covering layer</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B132.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>By day 5</strong></p>
<p><strong>Neovascularization reaches its peak</strong></p>
<p><strong>Granulation tissue fills the incisional space</strong></p>
<p><strong>Collagen fibrils become more abundant and begin to bridge the incision</strong></p>
<p><strong>The epidermis recovers its normal thickness</strong></p>
<p><strong>Differentiation of surface cells yields a mature epidermal architecture with surface keratinization</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B133.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Second week</strong></p>
<p><strong>Continued collagen accumulation and fibroblast proliferation</strong></p>
<p><strong>The leukocyte infiltrate, edema, and increased vascularity are substantially diminished</strong></p>
<p><strong>Increasing collagen deposition within the incisional scar</strong></p>
<p><strong>Regression of vascular channels</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B134.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>By the end of the first month</strong></p>
<p><strong>Scar consists of a cellular connective tissue</strong></p>
<p><strong>No inflammatory cells</strong></p>
<p><strong>Covered by a normal epidermis</strong></p>
<p><strong>Dermal appendages destroyed in the line of the incision are permanently lost The tensile strength of the wound increases with time</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B135.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention-2" class="title-slide slide level1 center">
<h1>Healing by Second Intention</h1>
<ul>
<li><strong>When cell or tissue loss is more extensive</strong></li>
<li><strong>Large wounds</strong></li>
<li><strong>Sites of abscess formation</strong></li>
<li><strong>Ulceration</strong></li>
<li><strong>Ischemic necrosis (infarction) in parenchymal organs</strong></li>
<li><strong>The repair process is more complex </strong>
<ul>
<li><strong>involves a combination of regeneration and scarring</strong></li>
</ul></li>
</ul>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B136.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention-secondary-union-1" class="title-slide slide level1 center">
<h1>Healing by Second Intention (secondary union)</h1>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B137.png" class="r-stretch"><p><strong>Inflammatory reaction is more intense</strong></p>
<p><strong>Abundant granulation tissue</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-by-second-intention-3" class="title-slide slide level1 center">
<h1>Healing by Second Intention</h1>
<p><strong>Accumulation of ECM and formation of a large scar</strong></p>
<p><strong>Followed by wound contraction by myofibroblasts</strong></p>

<img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B138.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="healing-of-skin-wounds-1" class="title-slide slide level1 center">
<h1>Healing of Skin Wounds</h1>
<p><strong>Wound strength</strong></p>
<p><strong>70% to 80% of normal by 3 months</strong></p>
<p><strong>Usually does not improve</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B139.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B140.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B141.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B142.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="img%5CYara-I%CC%87yiles%CC%A7mesi-ve-Tamir-kopyas%C4%B143.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="fibrosis-in-parenchymal-organs-1" class="title-slide slide level1 center">
<h1>Fibrosis in Parenchymal Organs</h1>
<p><strong>Excessive deposition of collagen and other ECM components in a tissue</strong></p>
<p><strong>Deposition of collagen in chronic diseases.</strong></p>
<p><strong>The basic mechanisms of fibrosis are the same as those of scar formation during tissue repair</strong></p>
<p><strong>Tissue repair occurs after a short-lived injurious stimulus, follows an orderly sequence of steps</strong></p>
<p><strong>Fibrosis is induced by persistent injurious stimuli </strong></p>
<p><strong>Responsible for organ dysfunction and even organ failure</strong></p>
<div class="footer footer-default">

</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="yara-iyilesmesi-ve-tamir_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Kopyalandı");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Kopyalandı");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>